Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.5177
-0.0150-2.82%
Post-market: 0.52000.0023+0.44%19:59 EDT
Volume:5.75M
Turnover:3.01M
Market Cap:143.92M
PE:-1.04
High:0.5480
Open:0.5400
Low:0.5104
Close:0.5327
52wk High:2.55
52wk Low:0.5104
Shares:278.00M
Float Shares:245.00M
Volume Ratio:1.65
T/O Rate:2.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:4.60
PE(LYR):-2.01

Loading ...

Humacyte Falls After Wider-than-Expected Quarterly Loss

Reuters
·
Aug 12

Humacyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Humacyte Q2 Net Loss Widens on Inventory, Production Costs

Reuters
·
Aug 12

Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate

Benzinga Earnings
·
Aug 12

Humacyte Q2 Cash & Investments USD 80.3 Million

THOMSON REUTERS
·
Aug 12

Humacyte Q2 Basic EPS USD -0.16

THOMSON REUTERS
·
Aug 12

Humacyte Q2 Operating Expenses USD 27.402 Million

THOMSON REUTERS
·
Aug 12

Humacyte Q2 Revenue USD 406 Thousand VS. Ibes Estimate USD 1.12 Million

THOMSON REUTERS
·
Aug 12

Press Release: Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 12

Humacyte Inc Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Humacyte Inc Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Humacyte Updates Financial Calendar, Sets Quarterly Results Webcast and Call

Reuters
·
Aug 07

Humacyte Gets NASDAQ Notice After Shares Trade Below $1 Bid-price Minimum

Reuters
·
Aug 01

Humacyte Price Target Maintained with a $2.00/Share by BTIG

Dow Jones
·
Jul 29

Humacyte Says FDA Accepts IND for First-in-human CTEV CABG Study

Reuters
·
Jul 27

Humacyte Announces FDA Acceptance of Ind for First-in-Human Clinical Study of Ctev for Coronary Artery Bypass Grafting

THOMSON REUTERS
·
Jul 27

Humacyte - to Initiate Phase 2a Ctev Study in Cabg This Quarter

THOMSON REUTERS
·
Jul 27

Humacyte Names Nephrologists Kossmann, Roy-chaudhury as Dialysis Access Advisors

Reuters
·
Jul 14

BTIG Remains a Buy on Humacyte (HUMA)

TIPRANKS
·
Jun 24

Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)

TIPRANKS
·
Jun 18